Scientific Program

Please, note that the time table of the scientific and social program is preliminary and may be subjected to minor modifications.

WEDNESDAY August 23, 2017

15.00- Registration


18.00-18.35 Embracing diversity to understand and conquer TB

Joel Ernst , New York University, USA

18.35-19.10 Lipoarabinomannan as a biomarker for TB

Gunilla Källenius , Karolinska Institutet, Sweden


THURSDAY August 24, 2017

08.20-08.30 Welcome

The local organizing committee

Chair: Professor Patric Brennan , Colorado State University, USA

08.30-09.05 cAMP signaling in mycobacteria: rounding a corner

Kathleen McDonough , University at Albany, USA

09.05-09.20 Or01: Connecting cell wall remodeling with extracellular vesicle production in Mycobacterium tuberculosis

Rafael Prados-Rosales , CICbioGUNE, Spain

09.20-09.35 Or02: Mycobacterium marinum phosphoinositide phosphatases modulate the phosphoinositide pattern of the pathogen vacuole and impact escape to the cytosol

Hendrik Koliwer-Brandl , University of Zürich, Switzerland

09.35-10.10 The ESX-1 secretion machinery

Roland Brosch , Insitut Pasteur, France

10.10-10.25 Or03: SOS-dependent mutasome recruitment and griselimycin-mediated inhibition of mutagenesis in live mycobacterial cells

Michael Reiche , CBTBR-University of Cape town, South Africa

10.25-10.55 COFFEE/POSTERS

Chair: Dr Bernadette Saunders , University of Sidney, Australia

10.55-11.30 Mycobacterium tuberculosis evasion of NADPH oxidase and LC3-associated phagocytosis

Jennifer Phillips , Washington University School of Medicine, USA

11.30-11.45 Or04: T cell priming instructs differentiation status, lung homing and protective capacity of CD4 memory cells against Mycobacterium tuberculosis infection

Thomas Lindenstrøm , Statens Serum Institut, Denmark

11.45-12.00 Or05: HIV inhibits the DC-T cell axis of macrophage activation by shifting Mycobacterium tuberculosis-specific CD4 T cells into a tolerogenic phenotype

Robert Blomgran , Linköping University, Sweden

12.00-13.00 LUNCH

Chair: Professor Christoph Lange , Research Center Borstel, Germany

13.00-13.35 The immune response to TB in exposed individuals

Simone Joosten , Leiden University Medical Center, the Netherlands

13.35-13.50 Or06: Differential recognition of MTB-specific epitopes as a function of disease history

Cecilia Lindestam Arlehamn , La Jolla Institute, USA

13.50-14.05 Or07: Phase III trial of the C-Tb skin test to diagnose Mycobacterium tuberculosis infection compared to tuberculin skin test and an interferon-γ release assay

Henrik Aggerbeck , Statens Serum Institut, Denmark

14.05-14.20 Or08: Increased mycobacterial susceptibility in a murine model of type 2 diabetes

Alim Md Abdul , James Cook University, Australia

14.20-15.20 POSTER SESSION 1: P01-18 (COFFEE will be provided)

Chair: Professor Andrea Cooper , University of Leicester, UK

15.20-15.55 MAIT cells and the mycobacterial metabolome

David Lewinsohn , Oregon Health & Sciences University, USA

15.55-16.10 Or09: Early and local immune mechanisms and tuberculosis disease progression in non-human primate species

Karin Dijkman , Biomedical Primate Research Centre, the Netherlands

16.10-16.25 Or10: In-situ sequencing of the TB granuloma

Martin Rottenberg , Karolinska Institutet, Sweden

16.25-16.40 Or11: Inhibition of tissue matrix metalloproteinases interferes with Mycobacterium tuberculosis-induced granuloma formation in a human lung tissue model

Clara Braian , Linköping University, Sweden


FRIDAY August 25, 2017

Chair: Professor David Lewinsohn , Oregon Health & Sciences University, USA

08.30-09.05 Immunological challenges in TB vaccine development

Hazel Dockrell , London School of Hygiene and Tropical Medicine, UK

09.05-09.20 Or12: Mucosal delivery of fusion proteins with Bacillus subtilis spores or nanoparticles enhances protection against TB

Peter Hart , University of London, UK

09.20-09.55 Vitamin D in the prevention and treatment of TB

Adrian Martineau , Queen Mary University of London, UK

09.55-10.10 Or13: Inhibition of tryptophan catabolism reorganizes the tuberculoma and augments the immune-mediated control of Mycobacterium tuberculosis

Deepak Kaushal , Tulane National Primate Research Center, USA

10.10-10.25 Or14: Identifying pathogenic IL-17-driven immune responses in active TB

Gabriele Pollara , University College London, UK

10.25-10.55 COFFEE/POSTERS

Chair: Professor Patric Brennan , Colorado State University, USA

10.55-11.30 Emerging treatments for TB

Andreas Diacon , TASK and Stellenbosch University, South Africa

11.30-11.45 Or15: Combination therapy for tuberculosis treatment: pulmonary administration of ethionamide and booster co-loaded nanoparticles

Joana Costa-Gouveia , Institut Pasteur de Lille, France

11.45-12.00 Or16: A novel derivative of the fungal antimicrobial peptide is bactericidal against Mycobacterium tuberculosis

Erik Tenland , Lund University, Sweden

12.00-13.00 LUNCH

Chair: Professor Andrea Cooper , University of Leicester, UK

13.00-13.35 Personalized MDR-TB treatment regimens

Jan Heyckendorf , Research Center Borstel, Germany

13.35-13.50 Or17: Genomic sequencing provides new ideas for TB management in Ukraine and identifies a pre-XDR outbreak

Olena Rzhepishevska , Umeå University, Sweden

13.50-14.25 Modelling the effects of TB treatment: from a molecular to a global scale

Emma McBryde , James Cook University, Australia

14.25-15.25 POSTER SESSION 2: P19-36 (COFFEE will be provided)

Chair: Professor Christoph Lange , Research Center Borstel, Germany

15.25-15.40 Or18: Detection and quantification of differentially culturable tubercle bacteria in sputum from tuberculosis patients

Bavesh Kana , CBTBR-University of the Witwatersrand and the National Health Laboratory Service, South Africa

15.40-15.55 Or19: Development of a diagnostic device for detection of Mycobacterium tuberculosis in air

Antonio Rothfuchs , Karolinska Institutet, Sweden

15.55-16.10 Or20: Identification of a miRNA biomarker panel in the plasma of tuberculosis patients.

Bernadette Saunders , University of Technology Sydney, Australia

16.10-16.45 Concluding remarks and future perspectives

Larry Schlesinger , Texas Biomedical Research Institute, USA



Akademikonferens - universities in cooperation

Karolinska Institutet, SLU and Uppsala University


phone: +46 18 67 15 33 or +46 18 67 10 03